11:34 AM
Dec 05, 2017
 |  BC Innovations  |  Distillery Therapeutics



Mouse studies suggest NMDA receptor antagonists could help treat autism caused by MEF2C haploinsufficiency. In an MEF2C-haploinsufficient mouse model of autism, NitroSynapsin, a memantine-based NMDA receptor antagonist, increased total hippocampal neurons...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >